Ravnefjord A, Brusberg M, Larsson H, Lindström E, Martínez V
AstraZeneca R&D, Integrative Pharmacology--GI Biology, Mölndal, Sweden.
Br J Pharmacol. 2008 Oct;155(3):407-16. doi: 10.1038/bjp.2008.259. Epub 2008 Jun 23.
Pregabalin, which binds to the alpha2-delta subunit of voltage-gated calcium channels, increased the threshold for pain during colorectal distension (CRD) in irritable bowel syndrome (IBS) patients. We tested the effects of oral pregabalin on the visceral pain-related viscerosomatic and autonomic cardiovascular responses to CRD and colonic compliance in rats.
The activity of the abdominal musculature (viscerosomatic response), monitored by electromyography and intracolonic manometry, and changes in blood pressure and heart rate, monitored by telemetry, were assessed simultaneously in conscious rats during CRD.
Pregabalin (10-200 micromol kg(-1), p.o.) inhibited dose dependently the viscerosomatic response to phasic, noxious CRD (12 distensions at 80 mm Hg). At 200 mumol kg(-1), pregabalin also reduced the increase in blood pressure and heart rate associated with noxious CRD. Moreover, pregabalin (200 micromol kg(-1), p.o.) reduced the visceromotor response to ascending phasic CRD (10-80 mm Hg) and significantly increased the threshold pressure for response. During phasic CRD (2-20 mm Hg), pregabalin (200 micromol kg(-1), p.o.) increased intracolonic volume, resulting in a shift to the left of the pressure-volume relationship curve, indicative of an increase of compliance.
Pregabalin reduced the viscerosomatic and autonomic responses associated with CRD-induced visceral pain and increased colonic compliance in rats. These observations confirm the analgesic activity of pregabalin on visceral pain and support the translational value of the CRD model to humans. Ligands for the alpha2-delta subunit might represent interesting compounds for the treatment of visceral pain disorders, such as IBS.
普瑞巴林可与电压门控钙通道的α2-δ亚基结合,能提高肠易激综合征(IBS)患者结肠扩张(CRD)时的疼痛阈值。我们测试了口服普瑞巴林对大鼠内脏痛相关的内脏-躯体及自主神经心血管反应以及结肠顺应性的影响。
在清醒大鼠进行CRD期间,通过肌电图监测腹部肌肉活动(内脏-躯体反应)、通过结肠内压力测定法监测结肠内压力变化,并通过遥测技术监测血压和心率变化。
普瑞巴林(10 - 200 μmol·kg⁻¹,口服)剂量依赖性地抑制了对阶段性、有害性CRD(80 mmHg下12次扩张)的内脏-躯体反应。在200 μmol·kg⁻¹时,普瑞巴林还降低了与有害性CRD相关的血压和心率升高。此外,普瑞巴林(200 μmol·kg⁻¹,口服)降低了对递增性阶段性CRD(10 - 80 mmHg)的内脏运动反应,并显著提高了反应的阈值压力。在阶段性CRD(2 - 20 mmHg)期间,普瑞巴林(200 μmol·kg⁻¹,口服)增加了结肠内体积,导致压力-体积关系曲线向左移动,表明顺应性增加。
普瑞巴林减轻了与CRD诱导的内脏痛相关的内脏-躯体和自主神经反应,并增加了大鼠的结肠顺应性。这些观察结果证实了普瑞巴林对内脏痛的镇痛活性,并支持CRD模型对人类的转化价值。α2-δ亚基的配体可能是治疗内脏痛疾病(如IBS)的有意义的化合物。